CRISPR Therapeutics (CRSP) News Today $40.98 -1.64 (-3.86%) As of 03:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period CRISPR Therapeutics Set To Reach Previous HeightsMarch 25 at 12:07 PM | seekingalpha.comMagnetar Financial LLC Buys New Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)Magnetar Financial LLC bought a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 9,125 shares of the company's stock, valued at approximately $359,0March 24 at 4:42 AM | marketbeat.comStockNews.com Upgrades CRISPR Therapeutics (NASDAQ:CRSP) to SellMarch 23 at 2:32 AM | americanbankingnews.com2 Beaten-Down Stocks to Buy on the DipMarch 22 at 4:04 PM | fool.comCRISPR Therapeutics (NASDAQ:CRSP) and MeiraGTx (NASDAQ:MGTX) Head to Head ComparisonMarch 22 at 1:33 AM | americanbankingnews.comContrarius Group Holdings Ltd Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP)Contrarius Group Holdings Ltd purchased a new position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 368,811 shares of the company's stock, valued at approximately $14,516,000March 21, 2025 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Upgraded by StockNews.com to "Sell" RatingStockNews.com upgraded shares of CRISPR Therapeutics to a "sell" rating in a report on Friday.March 21, 2025 | marketbeat.comKoss Olinger Consulting LLC Buys 18,298 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)Koss Olinger Consulting LLC increased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 115.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 34,168 shares of the company's stock after acquiring an additionaMarch 20, 2025 | marketbeat.comIs CRISPR Therapeutics (CRSP) One of the Most Shorted Stocks in 2025?March 19, 2025 | msn.com2 No-Brainer Biotech Stocks to Buy Right NowMarch 19, 2025 | fool.comNikko Asset Management Americas Inc. Decreases Position in CRISPR Therapeutics AG (NASDAQ:CRSP)Nikko Asset Management Americas Inc. decreased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 7.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,745,676 shares of the company's stock after selMarch 18, 2025 | marketbeat.comAnalysts Set CRISPR Therapeutics AG (NASDAQ:CRSP) PT at $73.11March 16, 2025 | americanbankingnews.comCRISPR Therapeutics AG (NASDAQ:CRSP) Receives $73.11 Consensus Price Target from BrokeragesCRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) has been given an average rating of "Hold" by the twenty-one research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and elMarch 16, 2025 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Shares Up 2.8% - Here's WhyCRISPR Therapeutics (NASDAQ:CRSP) Trading 2.8% Higher - What's Next?March 15, 2025 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 2.9% on Insider SellingMarch 15, 2025 | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 3.9% - Time to Sell?CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 3.9% - Time to Sell?March 14, 2025 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 2.9% on Insider SellingCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 2.9% on Insider SellingMarch 14, 2025 | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) COO Sells $50,819.16 in StockCRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) COO Julianne Bruno sold 1,198 shares of the firm's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the completion of the transaction, the chief operating officer now owns 8,263 shares of the company's stock, valued at approximately $350,516.46. The trade was a 12.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.March 13, 2025 | marketbeat.comJames R. Kasinger Sells 2,850 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) StockCRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) General Counsel James R. Kasinger sold 2,850 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $120,897.00. Following the completion of the sale, the general counsel now owns 77,530 shares of the company's stock, valued at $3,288,822.60. This trade represents a 3.55 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.March 13, 2025 | marketbeat.comInsider Selling: CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Sells 9,973 Shares of StockCRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) CEO Samarth Kulkarni sold 9,973 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $423,054.66. Following the transaction, the chief executive officer now directly owns 180,890 shares of the company's stock, valued at $7,673,353.80. The trade was a 5.23 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.March 13, 2025 | marketbeat.comCRISPR Therapeutics: An Uninspiring Start For CasgevyMarch 13, 2025 | seekingalpha.comCRISPR Therapeutics (NASDAQ:CRSP) Trading 1.1% Higher - Here's WhyCRISPR Therapeutics (NASDAQ:CRSP) Shares Up 1.1% - Here's What HappenedMarch 13, 2025 | marketbeat.comInsider Selling: CRISPR Therapeutics AG (NASDAQ:CRSP) COO Sells 1,198 Shares of StockMarch 13, 2025 | insidertrades.comCRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of "Hold" by BrokeragesCRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) has earned an average recommendation of "Hold" from the twenty-one analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and elMarch 13, 2025 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Shares Down 3.9% - Time to Sell?CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 3.9% - Should You Sell?March 11, 2025 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 3% - Time to Sell?CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 3% - Should You Sell?March 10, 2025 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Shares Up 0.9% - What's Next?CRISPR Therapeutics (NASDAQ:CRSP) Trading 0.9% Higher - Still a Buy?March 9, 2025 | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Oppenheimer & Co. Inc.Oppenheimer & Co. Inc. lowered its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 66.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,480 shares of the company's stock after selling 2March 8, 2025 | marketbeat.comCould buying this gene-editing penny stock at $1 make me rich?March 8, 2025 | msn.comCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 0.9% - Here's WhyCRISPR Therapeutics (NASDAQ:CRSP) Trading Up 0.9% - Should You Buy?March 7, 2025 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 1.9% - Should You Sell?CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 1.9% - Time to Sell?March 6, 2025 | marketbeat.comZacks Research Has Optimistic Outlook of CRSP Q2 EarningsCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at Zacks Research upped their Q2 2025 EPS estimates for shares of CRISPR Therapeutics in a note issued to investors on Tuesday, March 4th. Zacks Research analyst R. Department now forecasts that the company will earnMarch 6, 2025 | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) Holdings Raised by Vestmark Advisory Solutions Inc.Vestmark Advisory Solutions Inc. increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 40.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 244,034 shares of the company's stock after purchasing aMarch 6, 2025 | marketbeat.comSBI Securities Co. Ltd. Makes New $281,000 Investment in CRISPR Therapeutics AG (NASDAQ:CRSP)SBI Securities Co. Ltd. acquired a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 7,130 shares of the company's stock, valMarch 6, 2025 | marketbeat.comAnalysts Set Expectations for CRSP FY2027 EarningsCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Analysts at Zacks Research issued their FY2027 earnings per share estimates for CRISPR Therapeutics in a research report issued on Tuesday, March 4th. Zacks Research analyst R. Department expects that the company will earn ($4.62) per share forMarch 6, 2025 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0.5% - Time to Sell?CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0.5% - Here's What HappenedMarch 5, 2025 | marketbeat.comShareholders in CRISPR Therapeutics (NASDAQ:CRSP) are in the red if they invested a year agoMarch 5, 2025 | finance.yahoo.comCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0.9% - What's Next?CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0.9% - Here's WhyMarch 5, 2025 | marketbeat.comFY2027 Earnings Forecast for CRSP Issued By Zacks ResearchCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Analysts at Zacks Research issued their FY2027 earnings per share estimates for shares of CRISPR Therapeutics in a report released on Tuesday, March 4th. Zacks Research analyst R. Department anticipates that the company will earn ($4.62) per shMarch 5, 2025 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 1.7% - Time to Sell?CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 1.7% - What's Next?March 4, 2025 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0.5% - Should You Sell?CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0.5% - Here's WhyMarch 3, 2025 | marketbeat.comCRISPR Therapeutics AG (CRSP) TD Cowen 45th Annual Healthcare Conference (Transcript)March 3, 2025 | seekingalpha.comApril 11th Options Now Available For CRISPR Therapeutics (CRSP)March 1, 2025 | nasdaq.comCRISPR Therapeutics (NASDAQ:CRSP) Trading 4.7% Higher - Here's What HappenedCRISPR Therapeutics (NASDAQ:CRSP) Trading Up 4.7% - Should You Buy?March 1, 2025 | marketbeat.comJohn Greene Buys 7,000 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) StockCRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) Director John Greene purchased 7,000 shares of the firm's stock in a transaction on Wednesday, February 26th. The stock was bought at an average price of $44.85 per share, with a total value of $313,950.00. Following the acquisition, the director now owns 7,000 shares in the company, valued at $313,950. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.March 1, 2025 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Trading 1.2% Higher Following Insider Buying ActivityCRISPR Therapeutics (NASDAQ:CRSP) Trading Up 1.2% on Insider Buying ActivityFebruary 28, 2025 | marketbeat.comInsider Buying: John Greene Acquires Shares of CRISPR Therapeutics AGFebruary 28, 2025 | gurufocus.comJohn Greene Purchases 7,000 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) StockCRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) Director John Greene bought 7,000 shares of the company's stock in a transaction on Wednesday, February 26th. The stock was bought at an average cost of $44.85 per share, with a total value of $313,950.00. Following the completion of the purchase, the director now owns 7,000 shares of the company's stock, valued at approximately $313,950. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website.February 28, 2025 | marketbeat.comPrediction: CRISPR Therapeutics Will Beat the Market. Here's WhyFebruary 28, 2025 | fool.com3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.February 28, 2025 | fool.com Remove Ads Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address CRSP Media Mentions By Week CRSP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRSP News Sentiment▼0.710.63▲Average Medical News Sentiment CRSP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRSP Articles This Week▼911▲CRSP Articles Average Week Remove Ads Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Moderna News Neurocrine Biosciences News Exelixis News Bio-Techne News Vaxcyte News Qiagen News Repligen News Halozyme Therapeutics News Revolution Medicines News Krystal Biotech News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRSP) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRSP Stock Free CRSP Stock Alerts